Race Oncology Ltd. (AU:RAC) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Race Oncology Ltd. has submitted the necessary regulatory documents for a Phase 1 clinical trial of their RC220 bisantrene treatment, aimed at combating solid tumors. This trial will explore the safety and efficacy of RC220 in combination with doxorubicin, with patient recruitment expected to begin in Q1 2025. The study, which will take place across multiple sites in Australia, Hong Kong, and South Korea, could pave the way for larger international trials, enhancing treatment options for cancer patients.
For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.